Mactan Customs surpasses collection target

Mactan Customs surpasses collection target

By Junex Doronio
October 14, 2021

LAPU-LAPU CITY, Cebu — The Subport of Mactan of the Bureau of Customs Port of Cebu has exceeded its assigned collection target last month by more than P60 million.

Mactan Subport Assessment Section chief Nellie Wilwayco said their September collection target was P103,130,000.00 but they were able to collect P163,859,535.40.

With this actual collection as against the target collection, the surplus was P60,729,535.40, Wilwayco added.

Aside from its superb collection performance, the BOC-Cebu Subport of Mactan has also contributed much to the fight against the dreaded novel coronavirus disease (Covid-19).

Meanwhile, in its effort to help attain herd immunization, the BOC-Cebu Subport of Mactan has cleared a total of 1,212,120 doses of Pfizer BioNTech COVID-19 vaccine shipped in three batches.

Wilwayco said the first shipment containing 994,500 vaccine doses arrived on October 6, 2021 and was donated to the government by the World Health Organization-Global Alliance for Vaccines and Immunization (WHO-GAVI) through the United Nations Children’s Fund (UNICEF).

On the same day, another vaccine shipment containing 76,050 doses arrived in Mactan.

This is the largest single importation of Pfizer vaccines processed in the Subport of Mactan, the assessment section chief noted.

On October 7, Wilwayco said 141,570 more doses of the same vaccine arrived. Both shipments are private importation from Germany by Pfizer Inc.

The three batches of vaccine shipment were processed in advance prior to their arrival under the Subport’s One-Stop-Shop to ensure their prompt and unhampered release.


After the ramp release, the BOC COVAX Special Handling Team underguarded the vaccines until their delivery to the storage facility of the Department of Health Central Visayas Center for Health Development.

Wilwayco said since June 2021, the Subport of Mactan has cleared a total of 2,013,570 doses of Pfizer vaccine.

Leave a Reply